The brief

Analyst view

• Tryngolza (olezarsen) FDA-approved for familial chylomicronemia (Dec 2024) and severe hypertriglyceridemia (June 2026).
• Phase 3 CORE and CORE2 showed 49%-72% triglyceride reduction; first ASO to reduce acute pancreatitis.
• Breakthrough antisense medicine establishing the modality in lipid disorders market.

Technical approach

As reported

Antisense mechanism

Binding and blocking mRNA

ASOs are modified DNA/RNA that pair with target mRNA, causing cells to destroy it before protein translation.

APOC3 silencing

Reducing TG inhibition

Olezarsen targets APOC3 mRNA to block the protein that inhibits triglyceride breakdown.

Modality advantage

Longer-lasting than siRNA

ASOs trigger RNase H, which degrades the target RNA; they thus have longer duration of action than siRNA, allowing monthly rather than quarterly dosing.